+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Clinical Trial Grant

Cannonball Kids' Cancer Foundation

For the 2025 Grants Cycle, CKc will prioritize funding clinical trials and research that is nearing translation to a clinical trial. Grants funded by CKc must be innovative and provide better quality of life or symptom relief than current treatments.

Whenever possible, CKc will prioritize funding research with a focus on:

• cancers that are under-funded or under-researched.

• with a focus on patient populations who are traditionally underserved.

Whenever possible, CKc will prioritize funding researchers of diverse backgrounds.

Award Amount & Duration

$200,000 over 3 years

Program Specific Evaluation Criteria

• How many treatment options would this study provide for children?

• How accessible is this study for children and families to access?

AI Based Application Success Predictor

1. 🎯 Mission-Driven Focus: Pediatric Cancer

CKc funds only research that directly improves outcomes for children with cancer, especially when it:

Targets underfunded, rare, or pediatric-specific cancer types

Aims to develop less toxic, more effective treatments

Enhances quality of life and survivorship

💡 Strong Predictor: Clear pediatric focus; innovation targeted at survival and long-term wellness.

2. 🧪 Program-Relevant Grant Track

CKc offers two core funding streams:

Young Investigator Grant: ~$100,000 over 3 years — supports early careers to generate early-phase data.

Clinical Trial Grant: ~$200,000 over 3 years — supports first-in-human or Phase I–II trials.

✅ Predictor: Matching your career stage and research stage to the appropriate grant.

3. 🚀 Innovation with Translational Potential

Studies should be first-in-child or early clinical trials.

Projects must offer novel therapeutic strategies or biomarkers.

Proposals should focus on therapies with fewer side effects and better accessibility for diverse pediatric populations.

4. ✔️ Proven Feasibility & Strong Preliminary Data

Applications need well-rationalized preliminary data or proof-of-concept (especially for trial grants) or a clear early-career trajectory to full trials.

A structured and realistic timeline, milestones, and risk mitigation plan strengthen the application.

5. 👥 Track Record & Mentorship for Early Investigators

CKc emphasizes supporting clinical-investigator training pipelines.

Your profile should show a commitment to moving toward independent, trial-driving roles.

Mentorship, institutional support, and diverse backgrounds are prioritized.

6. 🔄 Rigorous Review Process & Pipeline Approach

Funding uses a two-stage LOI → full application process, reviewed by the CKc Scientific Advisory Board.

Only 17 full applications selected from 44 LOIs in the 2024 cycle—only 4 grants awarded.

CKc aims for high uptake of clinical trials—they report 94% of trial grants are novel.

7. 🌍 Equity, Diversity, & Access Priority

CKc favors projects focused on underserved or marginalized pediatric populations.

Researchers from diverse backgrounds and early-stage investigators are encouraged.

📅 Application Timeline & Process

LOI window: March 1 – June 1

Full application by: September 1

Awards begin: January 1 following year

CKc uses invite-only application after LOI and review.

✅ Summary Table

Predictor	Why It Matters
Pediatric focus	Foundation exclusively funds childhood-cancer research
Appropriate grant stream	Align career stage with Young Investigator vs. Trial
Translatable and novel approach	CKc supports first-of-kind and quality-of-life-enhancing therapies
Preliminary data & feasibility	Feasibility ensures funding confidence
Early career development	CKc invests in investigator pipelines
Multi-stage selection rigor	LOI success leads to competitive full application
DEI & underserved emphasis	Align with CKc’s mission for equitable impact

🔭 Why CKc Matters

CKc has committed over $4.5 million across more than 40 research grants in 35 U.S. states and international centers, generating 922 new treatment options for children. Many CKc-supported projects have led to NIH funding, clinical trial expansion, and lasting impact.

Specialties

Cancer

Eligibility Requirements

PI must hold an academic appointment at the Assistant Professor level or higher

• Preclinical studies must be complete

• If an FDA Investigational New Drug (IND) application is necessary for the proposed clinical study, the IND application should already have passed FDA initial review and be active

• If the PI has recruited additional patient enrollment sites, local IRB approval must be obtained for each site.

Sponsor Details

Sponsor Institute/Organizations: Cannonball Kids' Cancer Foundation

Sponsor Type: Corporate/Non-Profit

Address: 1555 Howell Branch Rd., Suite C202 Winter Park, FL 32789 321-325-5392 info@cannonballkidscancer.org

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity